1
00:00:02,200 --> 00:00:04,857
Sexual desire begins with signals in the brain.

2
00:00:04,901 --> 00:00:10,113
PT-141, also called bremelanotide, grew from
research into a family

3
00:00:10,113 --> 00:00:12,256
of messengers called melanocortins.

4
00:00:12,407 --> 00:00:16,735
By 2002, Palatin Technologies in Cranbury, New
Jersey, was reporting

5
00:00:16,735 --> 00:00:17,725
human trials.

6
00:00:17,904 --> 00:00:22,062
A 2003 paper by Peter Molinoff, Annette
Shadiack and colleagues

7
00:00:22,062 --> 00:00:23,376
described its development.

8
00:00:23,518 --> 00:00:27,565
That gives PT-141 more than two decades of
clinical research

9
00:00:27,565 --> 00:00:28,089
history.

10
00:00:28,162 --> 00:00:32,924
Bremelanotide is a ring-shaped peptide
containing seven amino acids.

11
00:00:33,080 --> 00:00:37,227
It activates several melanocortin receptors,
including receptors found in the

12
00:00:37,227 --> 00:00:37,712
brain.

13
00:00:37,902 --> 00:00:42,601
Its precise mechanism for improving low sexual
desire remains unknown.

14
00:00:42,789 --> 00:00:46,576
Early studies investigated sexual responses in
men.

15
00:00:46,684 --> 00:00:51,099
Later development focused on women experiencing
persistently low desire that

16
00:00:51,099 --> 00:00:52,128
caused distress.

17
00:00:52,300 --> 00:00:58,464
Two phase three RECONNECT trials randomized
1,267 premenopausal women to

18
00:00:58,464 --> 00:01:01,651
bremelanotide or placebo for twenty-four weeks.

19
00:01:01,839 --> 00:01:06,857
Women receiving bremelanotide reported greater
improvements in desire and reductions

20
00:01:06,857 --> 00:01:08,047
in related distress.

21
00:01:08,188 --> 00:01:11,281
The trials did not show a significant advantage
in the

22
00:01:11,281 --> 00:01:13,710
number of satisfying sexual events.

23
00:01:13,884 --> 00:01:19,593
In June 2019, the FDA approved Vyleesi for
acquired, generalized

24
00:01:19,593 --> 00:01:23,394
hypoactive sexual desire disorder in
premenopausal women.

25
00:01:23,526 --> 00:01:27,742
By 2026, that represents seven years since U.S.

26
00:01:27,742 --> 00:01:28,332
approval.

27
00:01:28,482 --> 00:01:32,252
This is a specific indication, not a general
sexual-performance claim.

28
00:01:32,402 --> 00:01:36,075
Nausea, flushing and headache are important
side effects.

29
00:01:36,239 --> 00:01:40,589
Blood pressure can temporarily rise, and the
medicine is contraindicated

30
00:01:40,770 --> 00:01:44,445
in uncontrolled hypertension or known
cardiovascular disease.

31
00:01:44,580 --> 00:01:49,815
PT-141 connects decades of peptide research
with a distinct approach

32
00:01:49,815 --> 00:01:53,985
to sexual health: studying desire, its
biological signals, and the

33
00:01:53,985 --> 00:01:56,203
distress that can accompany its loss.

34
00:01:56,375 --> 00:01:58,204
World Peptide Foundation.

35
00:01:58,369 --> 00:01:59,865
Peptides in 2.

36
00:02:00,015 --> 00:02:01,663
Every experience matters.